217 related articles for article (PubMed ID: 24012098)
1. Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Castellano D; Capdevila J; Sastre J; Alonso V; Llanos M; García-Carbonero R; Manzano Mozo JL; Sevilla I; Durán I; Salazar R
Eur J Cancer; 2013 Dec; 49(18):3780-7. PubMed ID: 24012098
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
[TBL] [Abstract][Full Text] [Related]
3. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
[TBL] [Abstract][Full Text] [Related]
4. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Simonelli M; Zucali PA; Lorenzi E; Rubino L; De Vincenzo F; De Sanctis R; Perrino M; Mancini L; Di Tommaso L; Rimassa L; Masci G; Zuradelli M; Suter MB; Bertossi M; Fattuzzo G; Giordano L; Roncalli MG; Santoro A
Eur J Cancer; 2013 Mar; 49(5):989-98. PubMed ID: 23146956
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Schwartzberg LS; Tauer KW; Hermann RC; Makari-Judson G; Isaacs C; Beck JT; Kaklamani V; Stepanski EJ; Rugo HS; Wang W; Bell-McGuinn K; Kirshner JJ; Eisenberg P; Emanuelson R; Keaton M; Levine E; Medgyesy DC; Qamar R; Starr A; Ro SK; Lokker NA; Hudis CA
Clin Cancer Res; 2013 May; 19(10):2745-54. PubMed ID: 23444220
[TBL] [Abstract][Full Text] [Related]
7. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
Mina LA; Yu M; Johnson C; Burkhardt C; Miller KD; Zon R
Invest New Drugs; 2013 Oct; 31(5):1307-10. PubMed ID: 23812905
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Yau T; Wong H; Chan P; Yao TJ; Pang R; Cheung TT; Fan ST; Poon RT
Invest New Drugs; 2012 Dec; 30(6):2384-90. PubMed ID: 22402942
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Vincenzi B; Silletta M; Schiavon G; Frezza AM; Del Vescovo R; Zobel BB; Santini D; Dei Tos AP; Tonini G
Expert Opin Investig Drugs; 2013 Jan; 22(1):1-7. PubMed ID: 23157681
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Gradishar WJ; Kaklamani V; Sahoo TP; Lokanatha D; Raina V; Bondarde S; Jain M; Ro SK; Lokker NA; Schwartzberg L
Eur J Cancer; 2013 Jan; 49(2):312-22. PubMed ID: 22954665
[TBL] [Abstract][Full Text] [Related]
15. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Erhardt A; Kolligs F; Dollinger M; Schott E; Wege H; Bitzer M; Gog C; Lammert F; Schuchmann M; Walter C; Blondin D; Ohmann C; Häussinger D
Cancer Chemother Pharmacol; 2014 Nov; 74(5):947-54. PubMed ID: 25173458
[TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
Bendell JC; Zakari A; Lang E; Waterhouse D; Flora D; Alguire K; McCleod M; Peacock N; Ruehlman P; Lane CM; Earwood C; Shih K
Cancer Invest; 2016 May; 34(5):213-9. PubMed ID: 27127841
[TBL] [Abstract][Full Text] [Related]
17. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Flaherty KT; Manola JB; Pins M; McDermott DF; Atkins MB; Dutcher JJ; George DJ; Margolin KA; DiPaola RS
J Clin Oncol; 2015 Jul; 33(21):2384-91. PubMed ID: 26077237
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
Sehgal R; Lembersky BC; Rajasenan KK; Crandall TL; Balaban EP; Pinkerton RA; Kane P; Schmotzer A; Zeh H; Potter DM; Ramanathan RK
Clin Colorectal Cancer; 2011 Jun; 10(2):117-20. PubMed ID: 21859564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]